The acquisition combines Personalis’s highly sensitive molecular residual disease (MRD) technology with Tempus’s commercial reach, multimodal data, and AI-enabled precision-oncology platform. TL;DR: Tempus AI’s proposed...read more
Category - Press Release
Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform
Acquisition brings together Personalis’ MRD technology with Tempus’ commercial scale, multimodal data and AI platform to advance cancer monitoring, deepen insights and accelerate growth Expands Tempus’ reach across the...read more
Abbott to acquire Exact Sciences
• Acquisition adds a new growth vertical to Abbott’s already high single-digit growth profile, gaining leadership in the fast-growing $60 billion U.S. cancer screening and precision oncology diagnostics segments•...read more
BEVIMI Launches: A New Bid to Bring Pharma-Grade Rigor to Brain Health
This past week, BEVIMI was officially announced. This new company aims to bring pharmaceutical-style rigor to the consumer brain-health market. Headquartered in Greenwich, Connecticut and led by co-founders Paul...read more
